Home
Companies
Catalysts
Deep Dives
Pelabresib
DAK539
PHASE3
Drug Profile
Modality
Small molecule
Route
Oral
Therapy Area
Oncology
Peak Sales Est
$2000M
Formulations
[]
Companies
NVS
(ORIGINATOR)
100%
Mechanism: BET inhibitor
Expert:
Bromodomain and extra-terminal domain inhibitor, modulating gene transcription
Everyday:
Blocks proteins that help cancer cells grow
Targets: ["BET"]
Programs (1)
Indication
Stage
Key Study
Regional Status
MF (JAK-naive)
PHASE3
MANIFEST-2
[]
Upcoming Catalysts (2)
Pelabresib - Myelofibrosis - EU Filing/Approval
2026
Pelabresib - Myelofibrosis - Ph3 - Start (MANIFEST-3)
2026
Notes
BET inhibitor (BRD2/3/4) for myelofibrosis in combination with ruxolitinib. First-in-class BET inhibitor in this indication; targets transcriptional dysregulation driving disease pathophysiology.
Data from Supabase · Updated 2026-03-24